Repare Therapeutics Taps Clementia Pharma’s Steve Forte As Its New CFO

Repare Therapeutics said Tuesday it has appointed Steve Forte as executive vice president and chief financial officer. The company, which has offices in Cambridge, MA and Montreal is developing immune-oncology drugs by leveraging a concept known as synthetic lethality. In 2017 it emerged from stealth with $68 million in outside financing to advance its efforts; in September it raised $82.5 million more.

Most recently Forte was CFO of Clementia Pharmaceuticals, which was acquired by French pharmaceutical company Ispen for $1.3 billion earlier this year. His previous experience includes nearly a decade at Aptalis Pharma, which was later acquired by Forest Labs (now part of Allergan (NYSE: [[ticker:AGN]])). Forte succeeds Katina Dorton, who joined Repare as CFO in May and has since left “to pursue other interests,” according to the company.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine. View all posts by Sarah de Crescenzo